In November 2018, Bristol-Myers Squibb opened the doors of its Cambridge R&D facility, to increase its focus on translational medicine and immuno-oncology (I-O) resistance, in addition to research across a number of other key disease states. Through its open-lab and open-office configuration, the site stresses the importance of collaboration, another theme mirrored in Sharon’s race experience.
“One of my all-time marathon highlights was running London in 2010. It was the slowest marathon of my life – I was injured and limped the whole way, but I had three friends who stayed with me the whole time, and it was such a great race,” Cload says. “In the lab, the same lessons apply. The work we do necessitates working together – we have an open environment where people from different scientific disciplines are mixed together, with the hope that we'll form new connections and be able to drive ideas forward more quickly.”
Bristol-Myers Squibb is at the starting line in Cambridge and Sharon is optimistic about the race ahead.
“I couldn't be more excited about getting started, and delivering on the promise of what this site can be - leveraging both the external environment and a great team of scientists here at Bristol-Myers Squibb,” Cload says. “It’s been a long journey here, and we’re ready to hit the ground running and deliver for patients.”